Hanne Bak - Zealand Pharma RD Director
| ZEAL Stock | DKK 650.00 1.00 0.15% |
Insider
Hanne Bak is RD Director of Zealand Pharma AS
| Age | 70 |
| Phone | 45 88 77 36 00 |
| Web | https://www.zealandpharma.com |
Zealand Pharma Management Efficiency
The company has return on total asset (ROA) of (0.4816) % which means that it has lost $0.4816 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.4412) %, meaning that it generated substantial loss on money invested by shareholders. Zealand Pharma's management efficiency ratios could be used to measure how well Zealand Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Magnus Agustsson | Danske Bank AS | 50 | |
| Martin Barlebo | Orsted AS | 52 | |
| Anders Pedersen | Orsted AS | N/A | |
| Rasmus Haervig | Orsted AS | N/A | |
| Henriette Ellekrog | Orsted AS | 57 | |
| Anu Kerns | Bavarian Nordic | 51 | |
| JeanChristophe May | Bavarian Nordic | 56 | |
| Laurence Moerlooze | Bavarian Nordic | 59 | |
| Tommy Nielsen | Vestas Wind Systems | 53 | |
| Johanna Norberg | Danske Bank AS | N/A | |
| Karsten Breum | Danske Bank AS | 51 | |
| Paul MSc | Bavarian Nordic | 56 | |
| Martin Blessing | Danske Bank AS | 56 | |
| Atilla Olesen | Danske Bank AS | N/A | |
| Anders Nielsen | Vestas Wind Systems | 61 | |
| Kerstin Knapp | Vestas Wind Systems | 48 | |
| Russell Thirsk | Bavarian Nordic | N/A | |
| Michael Ebbe | DSV Panalpina AS | 53 | |
| MarieLouise Aamund | DSV Panalpina AS | 51 | |
| Mathias Dalsten | Vestas Wind Systems | N/A | |
| Javier Diez | Vestas Wind Systems | 49 | |
Management Performance
| Return On Equity | -1.44 | |||
| Return On Asset | -0.48 |
Zealand Pharma AS Leadership Team
Elected by the shareholders, the Zealand Pharma's board of directors comprises two types of representatives: Zealand Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Zealand. The board's role is to monitor Zealand Pharma's management team and ensure that shareholders' interests are well served. Zealand Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Zealand Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Henriette Wennicke, Chief Officer | ||
| Lani Morvan, Investor Officer | ||
| Adam MD, Pres CEO | ||
| Hanne Bak, RD Director | ||
| Mads Kronborg, Head Communication | ||
| Ravinder Chahil, Sr Counsel | ||
| Christina Bredal, VP Organization | ||
| Danilo Verge, Head Affairs | ||
| Ivan Moller, Chief Officer | ||
| Jens MD, Head Pharmacology |
Zealand Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Zealand Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.44 | |||
| Return On Asset | -0.48 | |||
| Operating Margin | (3.82) % | |||
| Current Valuation | 10.33 B | |||
| Shares Outstanding | 51.28 M | |||
| Shares Owned By Insiders | 0.07 % | |||
| Shares Owned By Institutions | 56.21 % | |||
| Price To Earning | 12.66 X | |||
| Price To Book | 27.77 X | |||
| Price To Sales | 36.73 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Zealand Stock
Zealand Pharma financial ratios help investors to determine whether Zealand Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zealand with respect to the benefits of owning Zealand Pharma security.